News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
474,981 Results
Type
Article (26211)
Company Profile (119)
Press Release (448649)
Multimedia
Podcasts (37)
Webinars (11)
Section
Business (123520)
Career Advice (936)
Deals (28452)
Drug Delivery (88)
Drug Development (55988)
Employer Resources (70)
FDA (13168)
Job Trends (9976)
News (225199)
Policy (21973)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
Academia (1896)
Accelerated approval (31)
Adcomms (17)
Allergies (133)
Alliances (34157)
ALS (143)
Alzheimer's disease (1285)
Antibody-drug conjugate (ADC) (311)
Approvals (13555)
Artificial intelligence (532)
Autoimmune disease (202)
Automation (45)
Bankruptcy (221)
Best Places to Work (8477)
BIOSECURE Act (8)
Biosimilars (140)
Biotechnology (88)
Bladder cancer (155)
Brain cancer (63)
Breast cancer (519)
Cancer (4358)
Cardiovascular disease (341)
Career advice (805)
Career pathing (22)
CAR-T (272)
CDC (22)
Celiac Disease (1)
Cell therapy (681)
Cervical cancer (35)
Clinical research (49370)
Collaboration (1490)
Company closure (1)
Compensation (433)
Complete response letters (46)
COVID-19 (1833)
CRISPR (82)
C-suite (643)
Cystic fibrosis (105)
Data (5945)
Decentralized trials (3)
Denatured (12)
Depression (121)
Dermatology (45)
Diabetes (408)
Diagnostics (4942)
Digital health (45)
Diversity (6)
Diversity, equity & inclusion (22)
Drug discovery (242)
Drug pricing (121)
Drug shortages (24)
Duchenne muscular dystrophy (176)
Earnings (53353)
Editorial (37)
Employer branding (5)
Employer resources (66)
Events (64330)
Executive appointments (680)
FDA (16144)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1184)
Gene editing (178)
Generative AI (43)
Gene therapy (495)
GLP-1 (672)
Government (2950)
Grass and pollen (3)
Guidances (362)
Healthcare (13465)
HIV (61)
Huntington's disease (29)
IgA nephropathy (80)
Immunology and inflammation (193)
Immuno-oncology (63)
Indications (140)
Infectious disease (2065)
Inflammatory bowel disease (158)
Inflation Reduction Act (10)
Influenza (100)
Intellectual property (244)
Interviews (141)
IPO (11407)
IRA (33)
Job creations (1828)
Job search strategy (666)
JPM (36)
Kidney cancer (15)
Labor market (32)
Layoffs (260)
Leadership (16)
Legal (4504)
Liver cancer (83)
Longevity (20)
Lung cancer (582)
Lymphoma (357)
Machine learning (42)
Management (26)
Manufacturing (695)
MASH (136)
Medical device (11738)
Medtech (11799)
Mergers & acquisitions (18179)
Metabolic disorders (992)
mRNA (107)
Multiple sclerosis (154)
NASH (12)
Neurodegenerative disease (279)
Neuropsychiatric disorders (84)
Neuroscience (2403)
Neurotech (1)
NextGen: Class of 2026 (4367)
Non-profit (2489)
Now hiring (15)
Obesity (426)
Opinion (226)
Ovarian cancer (156)
Pain (182)
Pancreatic cancer (212)
Parkinson's disease (256)
Partnered (24)
Patents (486)
Patient recruitment (504)
Peanut (52)
People (34691)
Pharmaceutical (29)
Pharmacy benefit managers (22)
Phase 1 (15594)
Phase 2 (21630)
Phase 3 (16417)
Pipeline (6145)
Policy (168)
Postmarket research (1524)
Preclinical (6373)
Press Release (30)
Prostate cancer (224)
Psychedelics (26)
Radiopharmaceuticals (219)
Rare diseases (762)
Real estate (3150)
Recruiting (27)
Regulatory (18355)
Reports (30)
Research institute (1776)
Resumes & cover letters (162)
Rett syndrome (32)
RNA editing (13)
RSV (61)
Schizophrenia (145)
Series A (205)
Series B (149)
Service/supplier (7)
Sickle cell disease (80)
Special edition (11)
Spinal muscular atrophy (110)
Sponsored (40)
Startups (2310)
State (2)
Stomach cancer (12)
Supply chain (82)
Tariffs (34)
The Weekly (24)
Vaccines (696)
Venture capital (64)
Weight loss (255)
Women's health (68)
Worklife (9)
Date
Last 7 days (503)
Last 30 days (1933)
Last 365 days (22817)
2026 (6011)
2025 (23167)
2024 (26346)
2023 (29763)
2022 (38373)
2021 (40997)
2020 (39423)
2019 (32073)
2018 (24314)
2017 (22861)
2016 (20907)
2015 (24513)
2014 (17924)
2013 (14425)
2012 (15380)
2011 (16252)
2010 (14680)
Location
Africa (480)
Alabama (54)
Alaska (3)
Arizona (230)
Arkansas (11)
Asia (30492)
Australia (6221)
California (8923)
Canada (2625)
China (954)
Colorado (381)
Connecticut (445)
Delaware (263)
Europe (62301)
Florida (1530)
Georgia (239)
Hawaii (2)
Idaho (43)
Illinois (670)
India (75)
Indiana (441)
Iowa (15)
Japan (423)
Kansas (60)
Kentucky (30)
Louisiana (30)
Maine (58)
Maryland (1027)
Massachusetts (6308)
Michigan (236)
Minnesota (497)
Mississippi (4)
Missouri (114)
Montana (32)
Nebraska (15)
Nevada (116)
New Hampshire (75)
New Jersey (2639)
New Mexico (20)
New York (2559)
North Carolina (1026)
North Dakota (7)
Northern California (4483)
Ohio (281)
Oklahoma (11)
Oregon (25)
Pennsylvania (1728)
Puerto Rico (14)
Rhode Island (33)
South America (721)
South Carolina (66)
South Dakota (1)
Southern California (3431)
Tennessee (145)
Texas (1444)
United States (32053)
Utah (265)
Vermont (1)
Virginia (237)
Washington D.C. (43)
Washington State (792)
West Virginia (2)
Wisconsin (77)
Wyoming (1)
474,981 Results for "angioblast systems acquired by mesoblast limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
November 21, 2025
·
11 min read
Press Releases
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
September 4, 2025
·
6 min read
Press Releases
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
August 29, 2025
·
22 min read
Pharm Country
Mesoblast Corporate Presentation at Investor Conference - June 03, 2024
Mesoblast Limited, Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
June 2, 2024
·
5 min read
Press Releases
Laborie Acquires the JADA® System for Rapid Postpartum Hemorrhage Control, Expanding Obstetrics Portfolio
January 29, 2026
·
4 min read
Press Releases
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
July 1, 2025
·
5 min read
Policy
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, confirmed that it will file its Biologics License Application for approval of Ryoncil® in the treatment of children with steroid-refractory acute graft versus host disease with the U.S. Food and Drug Administration next week.
July 1, 2024
·
4 min read
Press Releases
Lee’s Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
December 10, 2025
·
6 min read
Press Releases
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
April 29, 2025
·
6 min read
Pharm Country
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mesoblast Limited announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023.
March 13, 2024
·
5 min read
Previous
2 of 47,499
Next
